Endogenous epoxygenases are modulators of monocyte/macrophage activity

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Bystrom, Jonas ^a   Wray, Jessica A ^a,d   Sugden, Mary C ^a   Holness, Mark J ^a   Swales, Karen E ^a,e   Warner, Timothy D ^a   Edin, Matthew L ^b   Zeldin, Darryl C ^b   Gilroy, Derek W ^c   Bishop Bailey, David ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; CYCLOOXYGENASE 2; CYTOCHROME P450 2C8; CYTOCHROME P450 2J2; EPOXYICOSATRIENOIC ACID; INTERLEUKIN 4; MANGANESE CHLORIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROADIFEN; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ARACHIDONATE EPOXYGENASE; CYP2C8 PROTEIN, HUMAN; CYTOCHROME P450; LIGAND; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; MACROPHAGE ACTIVATION; MONOCYTE; NORMAL HUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TRANSPORT; CELL STRAIN HEK293; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEK293 CELLS; HUMANS; IMMUNOMODULATION; INFLAMMATION; LIGANDS; MACROPHAGES; MONOCYTES; PPAR ALPHA; TRANSFECTION;

EID: 80054790076     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026591     Document Type: Article

References (41)

1. Mantovani A, Sica A, Locati M, (2005) Macrophage polarization comes of age. Immunity 23: 344-346.
2. Bishop-Bailey D, Wray J, (2003) Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat 71: 1-22.
3. Zeldin DC, (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276: 36059-36062.
4. Spiecker M, Liao JK, (2005) Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 433: 413-420.
5. Campbell WB, Fleming I. Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflugers Arch 459: 881-895.
6. Capdevila JH, Falck JR, Harris RC, (2000) Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41: 163-181.
7. Konkel A, Schunck WH. Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta 1814: 210-222.
8. Node K, Huo Y, Ruan X, Yang B, Spiecker M, et al. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276-1279.
9. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, et al. (2001) Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88: 44-51.
10. Wray JA, Sugden MC, Zeldin DC, Greenwood GK, Samsuddin S, et al. (2009) The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo. PLoS One 4: e7421.
11. Bishop-Bailey D, (2000) Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129: 823-834.
12. Yang B, Graham L, Dikalov S, Mason RP, Falck JR, et al. (2001) Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 60: 310-320.
13. Deng Y, Edin ML, Theken K N, Schuck RN, Flake GP, et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. Faseb J.
14. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. Faseb J24: 3770-3781.
15. Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS, et al. (2002) Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res 90: 1020-1027.
16. Werner K, Schaefer WR, Schweer H, Deppert WR, Karck U, et al. (2002) Characterization and identification of cytochrome P450 metabolites of arachidonic acid released by human peritoneal macrophages obtained from the pouch of Douglas. Prostaglandins Leukot Essent Fatty Acids 67: 397-404.
17. Yang W, Tuniki VR, Anjaiah S, Falck JR, Hillard CJ, et al. (2008) Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125i-14,15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther 324: 1019-1027.
18. Brown PJ, Stuart LW, Hurley KP, Lewis MC, Winegar DA, et al. (2001) Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg Med Chem Lett 11: 1225-1227.
19. MacKenzie A, Filippini S, Martin W, (1999) Effects of superoxide dismutase mimetics on the activity of nitric oxide in rat aorta. Br J Pharmacol 127: 1159-1164.
20. Wray J, Bishop-Bailey D, (2008) Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology. Exp Physiol 93: 148-154.
21. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, et al. (2005) The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A 102: 16747-16752.
22. Liu Y, Zhu Y, Rannou F, Lee TS, Formentin K, et al. (2004) Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells. Circulation 110: 1128-1133.
23. Harrington LS, Falck JR, Mitchell JA, (2004) Not so EEZE: the 'EDHF' antagonist 14, 15 epoxyeicosa-5(Z)-enoic acid has vasodilator properties in mesenteric arteries. Eur J Pharmacol 506: 165-168.
24. Moraes LA, Piqueras L, Bishop-Bailey D, (2006) Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110: 371-385.
25. Kaipainen A, Kieran MW, Huang S, Butterfield C, Bielenberg D, et al. (2007) PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One 2: e260.
26. Chen C, Wei X, Rao X, Wu J, Yang S,et al. Cytochrome P450 2J2 Is Highly Expressed in Hematologic Malignant Diseases and Promotes Tumor Cell Growth. J Pharmacol Exp Ther 336: 344-355.
27. Bhaskaran G, Nii A, Sone S, Ogura T, (1992) Differential effects of interleukin-4 on superoxide anion production by human alveolar macrophages stimulated with lipopolysaccharide and interferon-gamma. J Leukoc Biol 52: 218-223.
28. Abramson SL, Gallin JI, (1990) IL-4 inhibits superoxide production by human mononuclear phagocytes. J Immunol 144: 625-630.
29. Donnelly RP, Crofford LJ, Freeman SL, Buras J, Remmers E, et al. (1993) Tissue-specific regulation of IL-6 production by IL-4. Differential effects of IL-4 on nuclear factor-kappa B activity in monocytes and fibroblasts. J Immunol 151: 5603-5612.
30. Thieu VT, Nguyen ET, McCarthy BP, Bruns HA, Kapur R, et al. (2007) IL-4-stimulated NF-kappaB activity is required for Stat6 DNA binding. J Leukoc Biol 82: 370-379.
31. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, et al. (2007) CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics 17: 349-358.
32. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, et al. (2004) Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110: 2132-2136.
33. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC, (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271: 3460-3468.
34. Bain B, Pshyk K, (1972) Enhanced reactivity in mixed leukocyte cultures after separation of mononuclear cells on Ficoll-Hypaque. Transplant Proc 4: 163-164.
35. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, et al. (2009) M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 182: 4415-4422.
36. Martinez FO, Gordon S, Locati M, Mantovani A, (2006) Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 177: 7303-7311.
37. Harrington LS, Lundberg MH, Waight M, Rozario A, Mitchell JA. Reduced endothelial dependent vasodilation in vessels from TLR4(-/-) mice is associated with increased superoxide generation. Biochem Biophys Res Commun 408: 511-515.
38. Bishop-Bailey D, Hla T, Warner TD, (2002) Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. Circ Res 91: 210-217.
39. Donato MT, Gomez-Lechon MJ, Jover R, Nakamura T, Castell JV, (1998) Human hepatocyte growth factor down-regulates the expression of cytochrome P450 isozymes in human hepatocytes in primary culture. J Pharmacol Exp Ther 284: 760-767.
40. Zaric J, Ruegg C, (2005) Integrin-mediated adhesion and soluble ligand binding stabilize COX-2 protein levels in endothelial cells by inducing expression and preventing degradation. J Biol Chem 280: 1077-1085.
41. Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP,et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 25: 703-713.